|
Q3 FY2026
As of Jun 30, 2026
|
Q2 FY2026
As of Mar 31, 2026
|
Q1 FY2026
As of Dec 31, 2025
|
Q4 FY2025
As of Sep 30, 2025
|
Q3 FY2025
As of Jun 30, 2025
|
Q2 FY2025
As of Mar 31, 2025
|
Q1 FY2025
As of Dec 31, 2024
|
Q4 FY2024
As of Sep 30, 2024
|
Q3 FY2024
As of Jun 30, 2024
|
Q2 FY2024
As of Mar 31, 2024
|
Q1 FY2024
As of Dec 31, 2023
|
Q4 FY2023
As of Sep 30, 2023
|
Q3 FY2023
As of Jun 30, 2023
|
Q2 FY2023
As of Mar 31, 2023
|
Q1 FY2023
As of Dec 31, 2022
|
Q4 FY2022
As of Sep 30, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||
| Investments, at fair value | ||||||||||||||||
| Non-controlled/non-affiliate company investments | ||||||||||||||||
| Non-controlled affiliate company investments | ||||||||||||||||
| Controlled affiliate company investments | ||||||||||||||||
| Total investments, at fair value | ||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||
| Cash | ||||||||||||||||
| Cash equivalents | ||||||||||||||||
| Foreign currencies (cost of $7,132 and $11,685, respectively) | ||||||||||||||||
| Restricted cash and cash equivalents | ||||||||||||||||
| Restricted foreign currencies (cost of $0 and $1,219, respectively) | ||||||||||||||||
| Cash collateral held at broker for derivatives | ||||||||||||||||
| Restricted cash | ||||||||||||||||
| Restricted cash equivalents | ||||||||||||||||
| Interest receivable | ||||||||||||||||
| Receivable for investments | ||||||||||||||||
| Net unrealized appreciation on derivatives | ||||||||||||||||
| Other assets | ||||||||||||||||
| Total Assets | ||||||||||||||||
| Liabilities | ||||||||||||||||
| Debt | ||||||||||||||||
| Less unamortized debt issuance costs | ||||||||||||||||
| Debt less unamortized debt issuance costs | ||||||||||||||||
| Net unrealized depreciation on derivatives | ||||||||||||||||
| Interest payable | ||||||||||||||||
| Management and income incentive fees payable | ||||||||||||||||
| Accrued trustee fees | ||||||||||||||||
| Accounts payable and other liabilities | ||||||||||||||||
| Total Liabilities | ||||||||||||||||
| Net Assets | ||||||||||||||||
| Preferred stock, par value $0.001 per share, 1,000,000 shares authorized, zero shares issued and outstanding as of June 30, 2026 and September 30, 2025 | ||||||||||||||||
| Common stock, par value $0.001 per share, 500,000,000 shares authorized, 260,033,889 and 266,008,083 shares issued and outstanding as of June 30, 2026 and September 30, 2025, respectively | ||||||||||||||||
| Paid in capital in excess of par | ||||||||||||||||
| Distributable earnings (losses) | ||||||||||||||||
| Total Net Assets | ||||||||||||||||
| Total Liabilities and Total Net Assets | ||||||||||||||||
| Number of common shares outstanding (in shares) | ||||||||||||||||
| Net asset value per common share (in dollars per share) | ||||||||||||||||
| Common stock, shares authorized (in shares) | ||||||||||||||||
Loading...
